Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685568 · ClinicalTrials.gov registry record · Phase 1
Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00685568: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00685568 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00685568, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of celecoxib may keep polyps and colorectal cancer from forming in patients with familial adenomatous polyposis. PURPOSE: This randomized phase I trial is studying the side effects and best dose of celecoxib in treating young patients with a genetic predisposition for familial adenomatous polyposis.
Interventions
- OTHER placebo
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2002-11-21 |
| Est. Completion | 2006-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00685568
The ClinicalTrials.gov registry entry for NCT00685568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00685568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00685568 about?
NCT00685568 is a clinical study titled "Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of celecoxib may keep polyps and colorectal cancer from forming in patients with familial adenomatous polyposis. PURPOSE: This randomized phase I trial is studying the side effects and best dose of celecoxib...
What is the current status of trial NCT00685568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2002-11-21. Estimated completion is 2006-04-21.
What interventions are being tested in trial NCT00685568?
The interventions under investigation include: placebo (OTHER), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00685568?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.